HIBPRO

This brand name is authorized in Nigeria.

Active ingredients

The drug HIBPRO contains one active pharmaceutical ingredient (API):

1	Haemophilus influenzae B UNII F2TW0N64FI - HAEMOPHILUS INFLUENZAE TYPE B
	Haemophilus influenza type B (Hib) is a bacteria responsible for severe pneumonia, meningitis and other invasive diseases almost exclusively in young children. Vaccines are the only public health tool capable of preventing the majority of serious Hib disease.
	Read more about Haemophilus influenzae B

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-0200	Injection	HibPro Haemophilus Influenzae Type B Conjugate Vaccine INJ 0.5 mL 0.5 mL (1 dose) x 1's (in a vial)	Freeze-dried powder for solution for injection in a vial + diluent. Haemophilus influenzae Type b Conjugate Vaccine I.P. is a freeze-dried vaccine of purified polyribosyl ribitol phosphate capsular polysaccharide (PRP) of Hib, covalently bound to tetanus toxoid (carrier protein)	02/03/2022

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J07AG01	Haemophilus influenzae B, purified antigen conjugated	J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AG Haemophilus influenzae B vaccines
Discover more medicines within J07AG01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A6-0200